RI
ARTV

RTW Investments’s Artiva Biotherapeutics ARTV Stock Holding History

RTW Investments’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-148,844
Closed -$1.5M – 82
2024
Q4 		$1.5M Hold
148,844
– – 0.02% 68
2024
Q3 		$2.3M Buy
+148,844
New +$1.72M 0.03% 62

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments's ARTV Position: Q1 2025 in Review

RTW Investments sold out of Artiva Biotherapeutics (ARTV) in Q1 2025, closing a stake of 148,844 shares — an estimated $1.5M sold.

RTW Investments first reported a position in ARTV in Q3 2024 and held it in 2 quarters. The position peaked at $2.3M in Q3 2024. 53 funds tracked by Wall St. Rank hold ARTV as of Q1 2025.

  • RTW Investments reported no remaining Artiva Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • RTW Investments sold 148,844 Artiva Biotherapeutics shares in Q1 2025, an estimated $1.5M.
  • RTW Investments first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 2 quarters.
  • RTW Investments's Artiva Biotherapeutics position peaked at $2.3M in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2025.

Based on RTW Investments's 13F filing for Q1 2025, filed 15 May 2025.